The NxStage System One obtained 510(k) clearance in the United States and is CE marked for use in the EU for home haemodialysis, including home nocturnal haemodialysis. Its simplicity and revolutionary size are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy.

When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create ultrapure dialysis fluid. Unlike conventional haemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of a doctor or healthcare provider, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or while traveling and at a medically appropriate treatment frequency.

The System One is also used to provide a range of flexible therapy options in more traditional care settings such as hospitals and dialysis centres. Its safety and efficacy have been demonstrated by experience with more than 10 million treatments with thousands of patients around the world.

NxStage in the United Kingdom

In 2012, 54,824 adults in the UK received renal replacement therapy, an increase of 3.7% from 2011. The actual number of patients increased across all modalities: 2.3% increase in haemodialysis and 0.3% increase in peritoneal dialysis.1

The increase in the number of patients on haemodialysis has been associated with an increase in home haemodialysis. In the UK, the overall percentage of dialysis patients receiving haemodialysis has risen from 3.4% in 2011 to 4.0% in 2012.1

This follows the National Institute for Health and Care Excellence (NICE) guidelines in 2002 that suggested 10-15% of dialysis patients might opt for haemodialysis treatment at home with appropriate education.2


  1. UK Renal Registry, Sixteenth Annual Report, December 2013.
  2. NICE Guidance on home compared with hospital haemodialysis for patients with end-stage renal failure. September 2002;1-20.

APM1609 Rev. B